Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Return on Equity (2022 - 2025)

BioXcel Therapeutics has reported Return on Equity over the past 4 years, most recently at 0.71% for Q4 2025.

  • Quarterly results put Return on Equity at 0.71% for Q4 2025, down 19.0% from a year ago — trailing twelve months through Dec 2025 was 0.71% (down 19.0% YoY), and the annual figure for FY2025 was 0.69%, down 38.0%.
  • Return on Equity for Q4 2025 was 0.71% at BioXcel Therapeutics, up from 0.67% in the prior quarter.
  • Over the last five years, Return on Equity for BTAI hit a ceiling of 12.1% in Q3 2023 and a floor of 6.85% in Q2 2023.
  • Median Return on Equity over the past 4 years was 0.73% (2025), compared with a mean of 1.01%.
  • Peak annual rise in Return on Equity hit 847bps in 2024, while the deepest fall reached -1102bps in 2024.
  • BioXcel Therapeutics' Return on Equity stood at 1.61% in 2022, then skyrocketed by 327bps to 3.66% in 2023, then crashed by -76bps to 0.9% in 2024, then decreased by -21bps to 0.71% in 2025.
  • The last three reported values for Return on Equity were 0.71% (Q4 2025), 0.67% (Q3 2025), and 0.67% (Q2 2025) per Business Quant data.